-
The 2022 EASD Prospective | reduces the risk of diabetes by 61%, another finding from semaglutide
Time of Update: 2022-10-03
4mg/week) treatment can reduce the risk of type 2 diabetes in overweight or obese patients by more than 50%.
4mg/week) treatment can reduce the risk of type 2 diabetes in overweight or obese patients by more than 50%.
-
"2 mg/week", FDA approves larger dose of "semaglutide" for diabetes treatment
Time of Update: 2022-04-28
S. Food and Drug Administration recently approved a larger-strength (2 mg/week) weekly formulation of the GLP-1 receptor agonist semaglutide (Ozempic, Novo Nordisk) for adults with type 2 diabetes treatment .
FDA Okays Semaglutide Higher Dose, 2 mg/Week, for Type 2 Diabetes[EB/OL].
-
Lancet: In the treatment of type 2 diabetes, Eli Lilly's tirzepatide clinically defeated the "net celebrity hypoglycemic drug" semaglutide!
Time of Update: 2021-08-27
It is a dual GIP and GLP-1 receptor agonist that is injected once a week.
The data showed that compared with Novo Nordisk’s 1 mg injection semaglutide (semaglutide), three doses of Tirzepatide can significantly reduce the glycosylated hemoglobin and body weight of adult type II diabetes patients from the baseline level .
-
NEJM: For the treatment of type 2 diabetes, Tirzepatide is better than Semaglutide!
Time of Update: 2021-07-29
A recent phase 3 trial study published in NEJM showed that in patients with type 2 diabetes, tirzepatide is not inferior to and superior to semaglutide in terms of the average change in glycosylated hemoglobin levels from baseline to 40 weeks .
-
Novo Nordisk's high-dose semaglutide treatment application for diabetes is rejected by the FDA
Time of Update: 2021-04-27
0 mg once a week for treatment 2 Application for label extension for type-diabetes.
Although more information needs to be included in the resubmission, Novo Nordisk stated that the company believes that the completed clinical trial projects are sufficient to support semaglutide's label extension application.
-
Novo Nordisk's high-dose semaglutide treatment application for diabetes is rejected by the FDA
Time of Update: 2021-03-26
0 mg once a week for treatment 2 Application for label extension for type-diabetes.
Although more information needs to be included in the resubmission, Novo Nordisk stated that the company believes that the completed clinical trial projects are sufficient to support semaglutide's label extension application.
-
Lancet: Semaglutide helps obese type II diabetic patients lose weight
Time of Update: 2021-03-21
Diabetes Management Recently, researchers investigated the effect of the GLP-1 agonist semaglutide on overweight or obese type 2 diabetic patients.
Recently, researchers investigated the effect of the GLP-1 agonist semaglutide on overweight or obese type 2 diabetic patients.